Dr James Harrington, MBChB, MRCP
Clinical Endocrinology — NHS England (consultant endocrinologist)
Profile last reviewed: 2026-05-20
Dr Harrington is a consultant endocrinologist with clinical experience in GLP-1 agonist prescribing and growth hormone disorders. He reviews our clinical content, ensuring accuracy in dosing information, side effect profiles, and UK regulatory context.
Credentials
- MBChB — University of Manchester
- Member of the Royal College of Physicians (MRCP)
- Consultant in Clinical Endocrinology, NHS England
- Clinical experience with GLP-1 receptor agonist prescribing and GH-axis disorders
Professional registrations
- General Medical Council (GMC): Registered with a licence to practise
- Royal College of Physicians: Member (MRCP)
GMC registration number is verifiable on the GMC Medical Register by name. We do not republish registration numbers here to align with standard editorial practice on personal-data minimisation.
Role on the editorial board
Lead reviewer for clinical content — GLP-1 medicines, endocrine and metabolic conditions, prescribing context, and NHS pathway accuracy. Reviews the GLP-1 Centre and the metabolic-and-weight hub content.
Conflict of interest disclosures
- No equity in pharmaceutical companies, peptide manufacturers, or weight-management clinics.
- Has accepted CME-accredited educational sponsorship for endocrinology conferences from licensed pharmaceutical companies (declared annually per GMC standards).
- Does not accept consulting or advisory fees from online prescribing services or peptide retailers.
- Does not personally prescribe or supply any of the unlicensed peptides reviewed on this site.
Disclosures are reviewed annually and updated at the date shown above. See the conflict-of-interest policy for the wider framework.
Sections reviewed
- GLP-1 Centre — all brand and active-ingredient pages
- Metabolic and Weight hub and spokes
- Mounjaro / Wegovy / Ozempic side-effect pages
- GLP-1 pancreatitis, gallbladder, pregnancy & fertility explainers
Citation policy
Clinical claims must trace to NICE technology appraisals, MHRA Drug Safety Updates, the relevant Summary of Product Characteristics (SmPC), or peer-reviewed clinical trial publications. Off-label use is flagged as such with the appropriate UK regulatory framing.
The site-wide methodology is documented in our evidence grading methodology and editorial standards.
About the editorial board
Peptide Authority’s editorial board is responsible for the accuracy, evidence-grading, and UK regulatory framing of the content on this site. Read more about how we work in editorial standards and the corrections policy.
Other reviewers
- Dr Sarah Mitchell, PhD — Pharmacology and Peptide Therapeutics
- Dr Elena Kowalski, MSc, PhD — Molecular Biology and Immunology
- Dr David Chen, PharmD — Clinical Pharmacy and Regulatory Affairs